311 related articles for article (PubMed ID: 9628601)
61. A dose ranging study of photodynamic therapy with porfimer sodium (Photofrin) for treatment of basal cell carcinoma.
Oseroff AR; Blumenson LR; Wilson BD; Mang TS; Bellnier DA; Parsons JC; Frawley N; Cooper M; Zeitouni N; Dougherty TJ
Lasers Surg Med; 2006 Jun; 38(5):417-26. PubMed ID: 16788928
[TBL] [Abstract][Full Text] [Related]
62. Integral photodynamic treatment of refractory superficial bladder cancer.
Kriegmair M; Waidelich R; Lumper W; Ehsan A; Baumgartner R; Hofstetter A
J Urol; 1995 Oct; 154(4):1339-41. PubMed ID: 7658534
[TBL] [Abstract][Full Text] [Related]
63. Intravesical instillations with bacillus calmette-guérin for the treatment of carcinoma in situ involving prostatic ducts.
Palou Redorta J; Schatteman P; Huguet Pérez J; Segarra Tomás J; Rosales Bordes A; Algaba F; Villavicencio Mavrich H
Eur Urol; 2006 May; 49(5):834-8; discussion 838. PubMed ID: 16426729
[TBL] [Abstract][Full Text] [Related]
64. Cytohistologic correlation of urothelial lesions secondary to photodynamic therapy.
Broghamer WL; Parker JE; Harty JI; Gilkey CM
Acta Cytol; 1989; 33(6):881-6. PubMed ID: 2531527
[TBL] [Abstract][Full Text] [Related]
65. Whole bladder photodynamic therapy for transitional cell carcinoma of bladder.
Nseyo UO; Dougherty TJ; Boyle DG; Potter WR; Wolf R; Huben R; Pontes JE
Urology; 1985 Sep; 26(3):274-80. PubMed ID: 2930927
[TBL] [Abstract][Full Text] [Related]
66. Management of bacillus Calmette-Guerin (BCG) refractory superficial bladder cancer: results with intravesical BCG and Interferon combination therapy.
Punnen SP; Chin JL; Jewett MA
Can J Urol; 2003 Apr; 10(2):1790-5. PubMed ID: 12773228
[TBL] [Abstract][Full Text] [Related]
67. [A case of transitional cell carcinoma with squamous differentiation which developed squamous cell carcinoma in situ in the clinical course].
Sugiura S; Makiyama K; Yokomizo Y; Umemoto S; Miyoshi Y; Nakaigawa N; Ogawa T; Uemurai H; Yao M; Kubota Y; Yamanaka S
Hinyokika Kiyo; 2006 Sep; 52(9):715-8. PubMed ID: 17040058
[TBL] [Abstract][Full Text] [Related]
68. PHOTOFRIN-mediated photodynamic therapy for treatment of early stage oral cavity and laryngeal malignancies.
Schweitzer VG
Lasers Surg Med; 2001; 29(4):305-13. PubMed ID: 11746107
[TBL] [Abstract][Full Text] [Related]
69. Complications of whole bladder dihematoporphyrin ether photodynamic therapy.
Harty JI; Amin M; Wieman TJ; Tseng MT; Ackerman D; Broghamer W
J Urol; 1989 Jun; 141(6):1341-6. PubMed ID: 2524602
[TBL] [Abstract][Full Text] [Related]
70. A Phase I Study of Light Dose for Photodynamic Therapy Using 2-[1-Hexyloxyethyl]-2 Devinyl Pyropheophorbide-a for the Treatment of Non-Small Cell Carcinoma In Situ or Non-Small Cell Microinvasive Bronchogenic Carcinoma: A Dose Ranging Study.
Dhillon SS; Demmy TL; Yendamuri S; Loewen G; Nwogu C; Cooper M; Henderson BW
J Thorac Oncol; 2016 Feb; 11(2):234-41. PubMed ID: 26718878
[TBL] [Abstract][Full Text] [Related]
71. Topical mitomycin C therapy for carcinoma in situ of the bladder: a followup.
Stricker PD; Grant AB; Hosken BM; Taylor JS
J Urol; 1990 Jan; 143(1):34-5; discussion 35-6. PubMed ID: 2104637
[TBL] [Abstract][Full Text] [Related]
72. A phase 2 study of TMX-101, intravesical imiquimod, for the treatment of carcinoma in situ bladder cancer.
Donin NM; Chamie K; Lenis AT; Pantuck AJ; Reddy M; Kivlin D; Holldack J; Pozzi R; Hakim G; Karsh LI; Lamm DL; Belkoff LH; Belldegrun AS; Holden S; Shore N
Urol Oncol; 2017 Feb; 35(2):39.e1-39.e7. PubMed ID: 28341495
[TBL] [Abstract][Full Text] [Related]
73. Photodynamic therapy in the management of resistant lower urinary tract carcinoma.
Nseyo UO; Dougherty TJ; Sullivan L
Cancer; 1987 Dec; 60(12):3113-9. PubMed ID: 3677034
[TBL] [Abstract][Full Text] [Related]
74. Whole bladder wall photodynamic therapy with in situ light dosimetry for carcinoma in situ of the bladder.
D'Hallewin MA; Baert L; Marijnissen JP; Star WM
J Urol; 1992 Oct; 148(4):1152-5. PubMed ID: 1404627
[TBL] [Abstract][Full Text] [Related]
75. Commentary on "A phase II study of oportuzumab monatox: an immunotoxin therapy for patients with noninvasive urothelial carcinoma in situ previously treated with bacillus Calmette-Guérin." Kowalski M, Guindon J, Brazas L, Moore C, Entwistle J, Cizeau J, Jewett MA, MacDonald GC: J Urol 2012;188(5):1712-8 [Epub 2012 Sep 19].
See WA
Urol Oncol; 2013 Jul; 31(5):714. PubMed ID: 23796197
[TBL] [Abstract][Full Text] [Related]
76. Whole bladder wall photodynamic therapy for refractory carcinoma in situ of the bladder.
Uchibayashi T; Koshida K; Kunimi K; Hisazumi H
Br J Cancer; 1995 Mar; 71(3):625-8. PubMed ID: 7880749
[TBL] [Abstract][Full Text] [Related]
77. A phase I study of intravesical suramin for the treatment of superficial transitional cell carcinoma of the bladder.
Uchio EM; Linehan WM; Figg WD; Walther MM
J Urol; 2003 Jan; 169(1):357-60. PubMed ID: 12478189
[TBL] [Abstract][Full Text] [Related]
78. Phase I-II evaluation of intravesical novantrone (mitoxantrone) in superficial bladder cancer.
Sharifi R; Lee M; Clayton M; Lamb D; Siami P; Strub M; Albert D; Sarosdy M
Anticancer Drugs; 1991 Apr; 2(2):153-7. PubMed ID: 1958860
[TBL] [Abstract][Full Text] [Related]
79. Treatment of transitional cell carcinoma of the bladder with hematoporphyrin derivative phototherapy.
Benson RC; Kinsey JH; Cortese DA; Farrow GM; Utz DC
J Urol; 1983 Dec; 130(6):1090-5. PubMed ID: 6227755
[TBL] [Abstract][Full Text] [Related]
80. Long-term clinical outcomes of a phase I trial of intravesical docetaxel in the management of non-muscle-invasive bladder cancer refractory to standard intravesical therapy.
Laudano MA; Barlow LJ; Murphy AM; Petrylak DP; Desai M; Benson MC; McKiernan JM
Urology; 2010 Jan; 75(1):134-7. PubMed ID: 19913890
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
